Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B

doi:10.3748/wjg.v22.i18.4529

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7982)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-4) series.

Item

Count

PDF

539

WORD

214

HTML

3601

Figures (1-4)

266

Tables (1-4)

206

Sum=4826

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1095

Download

2061

Sum=3156

May 14, 2016 (publication date) through Jan 3, 2025

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

World J Gastroenterol. May 14, 2016; 22(18): 4529-4537
Published online May 14, 2016. doi: 10.3748/wjg.v22.i18.4529

Table 1 Demographic and clinical characteristics of study subjects at baseline

Parameters	Patients with CHB (n = 46)	Healthy controls (n = 43)
Age (yr)	34.5 (23.75-38.25)	34 (22-40)
Sex (M/F)	38/8	34/9
HBV DNA load (log₁₀ IU/mL)	7.71 (6.98-8.10)	NA
ALT level (U/L)	117.35^a (74.50-241.48)	14 (6-22)
AST level (U/L)	96.75^a (57.25-176.25)	12 (10-30)
HBsAg level (IU/mL)	7821.43 (3337.23-20737.14)	NA
HBsAg, pos/neg	46/0	0/43
HBeAg, pos/neg	46/0	0/43

Data are represented as median and interquartile range (IQR) or real case number. Normal values: ALT ≤ 50 IU/L; AST ≤ 40 IU/L; HBV DNA ≤ 1.78 log₁₀ IU/mL (60 IU/mL).

^aP < 0.05 vs the HCs. The undetectable HBV DNA loads were recorded as those ≤ 60 IU/mL. CHB: Chronic hepatitis B; HBV: Hepatitis B virus; NA: Not applicable; ALT: Alanine transferase; AST: Aspartate transferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; pos: Positive; neg: Negative.

Table 2 Dynamics of clinical parameters in patients with chronic hepatitis B during LdT treatment

Parameters	Baseline	3 mo	6 mo	9 mo	13 mo
HBV DNA load (log₁₀ IU/mL)	8.41 (7.68-8.80)	3.79^a (3.20-5.14)	3.04^a (2.48-3.98)	2.81^a (2.48-3.10)	2.48^a (2.48-3.50)
ALT level (U/L)	117.35 (74.50-241.48)	36.00^a (23.93-85.50)	27.00^a (22.00-38.00)	27.50^a (23.00-34.25)	29.50^a (24.00-55.00)
AST level (U/L)	96.75 (57.25-176.25)	34.00^a (28.00-55.25)	26.00^a (22.00-31.25)	24.50^a (19.75-30.00)	27.00^a (22.75-43.25)
HBsAg level (IU/mL)	7821.43 (3337.23-20737.14)	4214.99^a (2034.48-10170.46)	5153.19^a (2039.45-10671.30)	4414.88^a (2317.96-10084.21)	4210.48^a (1664.73-9823.78)

Data are represented as median and interquartile range (IQR). Normal values: ALT ≤ 50 IU/L; AST ≤ 40 IU/L; HBV DNA ≤ 1.78 log₁₀ IU/mL (60 IU/mL).

^aP < 0.05 vs baseline value. The undetectable HBV DNA loads were recorded as those ≤ 60 IU/mL. CHB: Chronic hepatitis B; HBV: Hepatitis B virus; ALT: Alanine transferase; AST: Aspartate transferase; HBsAg: Hepatitis B surface antigen.

Table 3 Comparison of demographic and clinical characteristics of patients with high and low interleukin-38 levels before treatment

Parameter	High IL-38 levelbefore treatment (n = 27)	Low IL-38 levelbefore treatment (n = 19)
Age (yr)	35 (23-38)	34 (25-40)
Sex (M/F)	22/5	16/3
HBV DNA load (log₁₀ IU/mL)	7.74 (6.89-8.10)	7.69 (7.14-8.36)
ALT level (U/L)	130.00 (71.00-246.50)	108.00 (81.00-147.00)
AST level (U/L)	156.00^c (76.00-193.00)	74.00 (49.00-147.00)
HBsAg level (IU/mL)	6641.55 (4437.10-18631.33)	10222.92 (2657.06-24877.19)

Data are represented as median and interquartile range (IQR) or real case number. Normal values: ALT ≤ 50 IU/L; AST ≤ 40 IU/L; HBV DNA ≤ 1.78 log₁₀ IU/mL (60 IU/mL).

^cP < 0.05 vs the group of patients with low serum IL-38 levels before LdT treatment. The undetectable HBV DNA loads were recorded as those ≤ 60 IU/mL. High IL-38 level: Serum IL-38 ≥ 250 pg/mL; Low IL-38 level: Serum IL-38 < 250 pg/mL; IL-38: Interleukin-38; HBV: Hepatitis B virus; ALT: Alanine transferase; AST: Aspartate transferase; HBsAg: Hepatitis B surface antigen; M: Male; F: Female.

Table 4 Comparison of treatment outcomes between patients with high and low baseline interleukin-38 levels

Parameters	Week 24			Week 52
Parameters	HG (n = 27)	LG (n = 19)	P value	HG (n = 27)	LG (n = 19)	P value
HBV DNA ≤ 60 IU/mL	13 (48.1)	3 (15.8)	0.023	18 (66.7)	7 (36.8)	0.044
HBeAg seroconversion	4 (14.8)	2 (10.5)	0.516	8 (29.6)	4 (21.1)	0.382
ALT normalization	25 (92.6)	15 (78.9)	0.182	21 (77.8)	12 (63.2)	0.225
HBsAg loss	0 (0.0)	0 (0.0)	NA	1 (3.7)	1 (5.3)	0.661

Normal values: ALT ≤ 50 IU/L; AST ≤ 40 IU/L; HBV DNA ≤ 1.78 log10 IU/mL (60 IU/mL). The undetectable HBV DNA loads were recorded as those ≤ 60 IU/mL. HG: High IL-38 level group, basement serum IL-38 ≥ 250 pg/mL; LG: Low IL-38 level, basement serum IL-38 < 250 pg/mL; IL-38: Interleukin-38; HBV: Hepatitis B virus; ALT: Alanine transferase; AST: Aspartate transferase; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen; NA: Not applicable.

Citation: Wang HJ, Jiang YF, Wang XR, Zhang ML, Gao PJ. Elevated serum interleukin-38 level at baseline predicts virological response in telbivudine-treated patients with chronic hepatitis B. World J Gastroenterol 2016; 22(18): 4529-4537
URL: https://www.wjgnet.com/1007-9327/full/v22/i18/4529.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i18.4529